Advertisement

Effect of Cis-Compound Variants in MYH7 on Hypertrophic Cardiomyopathy With a Mild Phenotype

Published:January 20, 2022DOI:https://doi.org/10.1016/j.amjcard.2021.11.049
      Patients with hypertrophic cardiomyopathy (HC) caused by compound variants have severe clinical manifestations, but significant clinical heterogeneity remains. Clinical diversity in these patients may result from different combinations of variants. We analyzed the role of cis-compound variants in a Chinese HC pedigree. Exome sequencing was performed in the proband. Identified variants were detected with bi-directional Sanger sequencing in a pedigree that comprised 3 generations and 28 family members. Follow-up was performed for 16 years. Two missense variants (c.2465T>C, p.Met822Thr; c.4258C>T, p.Arg1420Trp) were identified in the MYH7 gene. These variants were absent in our 761 in-house people without HC and predicted to be pathogenic.Both variants were detected in 11 family members, thus they were believed to inherit cis. In the 11 members, only 5 developed HC, the other 6 were asymptomatic variant carriers with an abnormal electrocardiogram. The HC members had mild hypertrophy with a maximum left ventricular wall thickness of 13 to 21 mm and showed a low incidence of cardiovascular events. In conclusion, the cis-compound variants of Met822Thr and Arg1420Trp in MYH7 are causal but relatively benign, variants associated with familial HC. This finding suggests that different types of compound variants might need to be analyzed for a genotype–phenotype study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Maron BJ.
        Hypertrophic cardiomyopathy: a systematic review.
        JAMA. 2002; 287: 1308-1320
        • Zou Y
        • Song L
        • Wang Z
        • Ma A
        • Liu T
        • Gu H
        • Lu S
        • Wu P
        • Zhang dagger Y
        • Shen dagger L
        • Cai Y
        • Zhen double dagger Y
        • Liu Y
        • Hui R.
        Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults.
        Am J Med. 2004; 116: 14-18
        • Erdmann J
        • Daehmlow S
        • Wischke S
        • Senyuva M
        • Werner U
        • Raible J
        • Tanis N
        • Dyachenko S
        • Hummel M
        • Hetzer R
        • Regitz-Zagrosek V.
        Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy.
        Clin Genet. 2003; 64: 339-349
        • Van Driest SL
        • Vasile VC
        • Ommen SR
        • Will ML
        • Tajik AJ
        • Gersh BJ
        • Ackerman MJ.
        Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2004; 44: 1903-1910
        • Berge KE
        • Leren TP.
        Genetics of hypertrophic cardiomyopathy in Norway.
        Clin Genet. 2014; 86: 355-360
        • Wang J
        • Wang Y
        • Zou Y
        • Sun K
        • Wang Z
        • Ding H
        • Yuan J
        • Wei W
        • Hou Q
        • Wang H
        • Liu X
        • Zhang H
        • Ji Y
        • Zhou X
        • Sharma RK
        • Wang D
        • Ahmad F
        • Hui R
        • Song L.
        Malignant effects of multiple rare variants in sarcomere genes on the prognosis of patients with hypertrophic cardiomyopathy.
        Eur J Heart Fail. 2014; 16: 950-957
        • Richard P
        • Isnard R
        • Carrier L
        • Dubourg O
        • Donatien Y
        • Mathieu B
        • Bonne G
        • Gary F
        • Charron P
        • Hagege M
        • Komajda M
        • Schwartz K
        • Hainque B.
        Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy.
        J Med Genet. 1999; 36: 542-545
        • Maron BJ
        • Maron MS
        • Semsarian C.
        Double or compound sarcomere mutations in hypertrophic cardiomyopathy: a potential link to sudden death in the absence of conventional risk factors.
        Heart Rhythm. 2012; 9: 57-63
        • Zou Y
        • Wang J
        • Liu X
        • Wang Y
        • Chen Y
        • Sun K
        • Gao S
        • Zhang C
        • Wang Z
        • Zhang Y
        • Feng X
        • Song Y
        • Wu Y
        • Zhang H
        • Jia L
        • Wang H
        • Wang D
        • Yan C
        • Lu M
        • Zhou X
        • Song L
        • Hui R.
        Multiple gene mutations, not the type of mutation, are the modifier of left ventricle hypertrophy in patients with hypertrophic cardiomyopathy.
        Mol Biol Rep. 2013; 40: 3969-3976
        • Williams JR.
        The Declaration of Helsinki and public health.
        Bull World Health Organ. 2008; 86: 650-652
        • McKenna WJ
        • Spirito P
        • Desnos M
        • Dubourg O
        • Komajda M.
        Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families.
        Heart. 1997; 77: 130-132
        • Richards S
        • Aziz N
        • Bale S
        • Bick D
        • Das S
        • Gastier-Foster J
        • Grody WW
        • Hegde M
        • Lyon E
        • Spector E
        • Voelkerding K
        • Rehm HL
        ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
        Genet Med. 2015; 17: 405-424
        • Song L
        • Zou Y
        • Wang J
        • Wang Z
        • Zhen Y
        • Lou K
        • Zhang Q
        • Wang X
        • Wang H
        • Li J
        • Hui R.
        Mutations profile in Chinese patients with hypertrophic cardiomyopathy.
        Clin Chim Acta. 2005; 351: 209-216
        • Van Driest SL
        • Jaeger MA
        • Ommen SR
        • Will ML
        • Gersh BJ
        • Tajik AJ
        • Ackerman MJ.
        Comprehensive analysis of the beta-myosin heavy chain gene in 389 unrelated patients with hypertrophic cardiomyopathy.
        J Am Coll Cardiol. 2004; 44: 602-610
        • Ho CY
        • Lever HM
        • DeSanctis R
        • Farver CF
        • Seidman JG
        • Seidman CE.
        Homozygous mutation in cardiac troponin T: implications for hypertrophic cardiomyopathy.
        Circulation. 2000; 102: 1950-1955
        • Jeschke B
        • Uhl K
        • Weist B
        • Schröder D
        • Meitinger T
        • Döhlemann C
        • Vosberg HP.
        A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes.
        Hum Genet. 1998; 102: 299-304
        • Tsoutsman T
        • Kelly M
        • Ng DC
        • Tan JE
        • Tu E
        • Lam L
        • Bogoyevitch MA
        • Seidman CE
        • Seidman JG
        • Semsarian C.
        Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy.
        Circulation. 2008; 117: 1820-1831
        • Viswanathan SK
        • Sanders HK
        • McNamara JW
        • Jagadeesan A
        • Jahangir A
        • Tajik AJ
        • Sadayappan S.
        Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.
        PLoS One. 2017; 12e0187948
        • Walsh R
        • Rutland C
        • Thomas R
        • Loughna S.
        Cardiomyopathy: a systematic review of disease-causing mutations in myosin heavy chain 7 and their phenotypic manifestations.
        Cardiology. 2010; 115: 49-60
        • Colegrave M
        • Peckham M.
        Structural implications of β-cardiac myosin heavy chain mutations in human disease.
        Anat Rec (Hoboken). 2014; 297: 1670-1680
        • Venselaar H
        • Te Beek TA
        • Kuipers RK
        • Hekkelman ML
        • Vriend G
        Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces.
        BMC Bioinformatics. 2010; 11: 548
        • Taylor KC
        • Buvoli M
        • Korkmaz EN
        • Buvoli A
        • Zheng Y
        • Heinze NT
        • Cui Q
        • Leinwand LA
        • Rayment I.
        Skip residues modulate the structural properties of the myosin rod and guide thick filament assembly.
        Proc Natl Acad Sci U S A. 2015; 112: E3806-E3815
        • Alpert NR
        • Mohiddin SA
        • Tripodi D
        • Jacobson-Hatzell J
        • Vaughn-Whitley K
        • Brosseau C
        • Warshaw DM
        • Fananapazir L.
        Molecular and phenotypic effects of heterozygous, homozygous, and compound heterozygote myosin heavy-chain mutations.
        Am J Physiol Heart Circ Physiol. 2005; 288: H1097-H1102
        • Maron BJ
        • Maron MS
        • Semsarian C.
        Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.
        J Am Coll Cardiol. 2012; 60: 705-715